Loading
Virbac Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 24 Jul 2023.
Virbac: what insiders have been doing
Every trade that managers of Virbac disclose to AMF is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Carros, France. It was founded in 1968. Virbac has had no insider filing for more than a year; the last one goes back to 19 April 2024.
Looking back to 2021, when coverage begins, insiders filed 4 purchases and 7 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€1M
4 ops. · all time
Sell Volume
€4M
7 ops. · all time
Since the insiders bought
- +20.6%Entry €283.50 · Close at T+365 €342.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Virbac Strong Buy (bullish), based on 8 analysts. Average price target: €412.75.
Fundamental score
Ranked 4,541 of 24,148 companies
67.6
score / 100
Value61
Quality74
FCF yld3.6%
Earn yld5.7%
EV/EBITDA10.3x
ROE14%
Gross mgn67%
Net mgn10%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€317.50
Analyst consensus
8 analystsStrong buy
€360.00Target €412.75(+30%)€440.00
Income statement
Revenue€1.5B
Gross profit€975.2M67% margin
EBITDA€286.9M20% margin
Net income€150.9M10.4% margin
Valuation
PER (trailing)17.1x
PER (forward)13.8x
P/Book2.2x
Beta0.79
Balance sheet & cash
Market cap€2.7B
Total debt€288.8M
Free Cash Flow€96.8M
Debt / Equity30%
Profitability & ownership
ROE13.6%
ROA7.6%
% insiders50.8%
% institutions25.7%
Last declaration on 19 April 2024
Declarations11 total
3,008 shares@ €365.038824.9% of flowActionEuronext ParisISIN FR00000315772024DD961105
950 shares@ €258.005.6% of flowActionEuronext ParisISIN FR00000315772023DD920571
Canonical exit: 17 Oct 2023 (T+90)
240 shares@ €412.002.2% of flowActionEuronext ParisISIN FR00000315772021DD796630
1,000 shares@ €385.008.7% of flowActionEuronext ParisISIN FR00000315772021DD771511
2,000 shares@ €384.041817.4% of flowActionEuronext ParisISIN FR00000315772021DD771510
1,807 shares@ €342.2814.0% of flowActionEuronext ParisISIN FR00000315772021DD766963
1,000 shares@ €342.31100.0% of flowActionEuronext ParisISIN FR00000315772021DD766962
822 shares@ €340.536.3% of flowActionEuronext ParisISIN FR00000315772021DD766589
280 shares@ €212.001.3% of flowActionEuronext ParisISIN FR00000315772021DD737518
Canonical exit: 17 Jun 2021 (T+90)
310 shares@ €235.001.7% of flowActionEuronext ParisISIN FR00000315772021DD737517
Canonical exit: 16 Jun 2021 (T+90)
3,350 shares@ €234.955217.8% of flowActionEuronext ParisISIN FR00000315772021DD737516
Canonical exit: 16 Jun 2021 (T+90)
11 of 11 declarations
About Virbac
Virbac is a global animal health company focused on the development, manufacturing and commercialization of solutions for veterinarians, farmers and pet owners. The group offers a broad and practical portfolio spanning companion animals and farm animals, with products and services that address key therapeutic and preventive needs. Its ranges include antiparasitics, dermatology treatments, oral health products, mobility solutions, reproduction-related products, specialty nutrition, and preventive and therapeutic solutions for ruminants and other livestock. Virbac operates in more than 100 countries and maintains manufacturing sites and R&D centers across five continents, giving it a substantial international industrial and commercial footprint.
Virbac was founded in 1968 by veterinarian Pierre-Richard Dick in Carros, near Nice, France, with the ambition of creating medicines specifically designed for animal health. Over time, the company expanded through a combination of internal innovation and targeted acquisitions, while remaining centered on veterinary medicine. This long-term strategy helped Virbac build a strong reputation among animal health professionals, especially through differentiated products and a close relationship with veterinarians. The company also emphasizes a sustained innovation culture, supported by regular R&D investment and the launch of solutions aimed at unmet or under-served medical needs.
Read moreShow less
Strategically, Virbac stands out for its balanced mix of specialty products and broader core ranges, as well as for its diversified geographic exposure. Europe remains a key region, but the group also holds meaningful positions in North America, Asia-Pacific, Latin America, India and the Middle East/Africa. Full-year 2025 results showed solid commercial momentum, with revenue reaching €1.465 billion, up 4.8% on a reported basis and 7.9% at constant exchange rates and scope. Growth was supported by companion-animal momentum, specialty launches and targeted acquisitions such as Sasaeah in Japan and Mopsan in Türkiye. Virbac also announced that Paul Martingell would become CEO effective September 1, 2025, marking a new phase in the company’s international development.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
